Significance MM3122 represents an advanced lead candidate for clinical development as a novel antiviral drug for COVID-19. In addition to being novel drugs, these selective TMRSS2 inhibitors can be used as valuable chemical probes to help elucidate mechanisms of viral pathogenesis. Since TMPRSS2 plays a key role as a viral protein processing protease in the pathogenesis of other coronaviruses (SARS-CoV, MERS-CoV) as well as influenza viruses, MM3122 and this class of TMPRSS2 inhibitors hold much promise as new drugs to not only treat SARS-CoV-2 infections but also potentially represent broad-spectrum antivirals. The host cell serine protease TMPRSS2 is an attractive therapeutic target for COVID-19 drug discovery. This protease activates the Spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and of other coronaviruses and is essential for viral spread in the lung. Utilizing rational structure-based drug design (SBDD) coupled to substrate specificity screening of TMPRSS2, we have discovered covalent small-molecule ketobenzothiazole (kbt) TMPRSS2 inhibitors which are structurally distinct from and have significantly improved activity over the existing known inhibitors Camostat and Nafamostat. Lead compound MM3122 (4) has an IC 50 (half-maximal inhibitory concentration) of 340 pM against recombinant full-length TMPRSS2 protein, an EC 50 (half-maximal effective concentration) of 430 pM in blocking host cell entry into Calu-3 human lung epithelial cells of a newly developed VSV-SARS-CoV-2 chimeric virus, and an EC 50 of 74 nM in inhibiting cytopathic effects induced by SARS-CoV-2 virus in Calu-3 cells. Further, MM3122 blocks Middle East respiratory syndrome coronavirus (MERS-CoV) cell entry with an EC 50 of 870 pM. MM3122 has excellent metabolic stability, safety, and pharmacokinetics in mice, with a half-life of 8.6 h in plasma and 7.5 h in lung tissue, making it suitable for in vivo efficacy evaluation and a promising drug candidate for COVID-19 treatment.
【저자키워드】 COVID-19, Antiviral, Protease inhibitor, structure-based drug discovery, PS-SCL, TMPRSS2, 【초록키워드】 Treatment, SARS-CoV-2, Efficacy, coronavirus, Pathogenesis, Drug discovery, drug design, SARS-CoV, Influenza, SARS-COV-2 infection, viral pathogenesis, drugs, lung, SARS-CoV-2 virus, pharmacokinetics, drug, protease, severe acute respiratory syndrome Coronavirus, viral spread, virus, MERS-CoV, Spike protein, antiviral drug, COVID-19 treatment, Protein, specificity, stability, Viral, mice, human lung, Middle East respiratory syndrome Coronavirus, influenza viruses, nafamostat, broad-spectrum antivirals, plasma, epithelial cells, camostat, respiratory, in vivo, inhibitor, SARS-CoV-2 infections, Calu-3, mechanism, half-life, Cytopathic effect, calu-3 cells, Middle East respiratory syndrome, Middle East, epithelial cell, therapeutic target, chimeric, lead, host cell, TMPRSS2 inhibitors, acute respiratory syndrome, half-maximal inhibitory concentration, Serine, Viral protein, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, other coronaviruses, cell entry, help, clinical development, lung tissue, treat, serine protease TMPRSS2, TMPRSS2 inhibitor, Calu, respiratory syndrome coronavirus, drug candidate, cytopathic effects, selective, TMPRSS2 protein, full-length, probe, block, half-maximal effective concentration, significantly, addition, can be used, other coronavirus, activate, inhibiting, the Spike, Significance, 【제목키워드】 SARS-CoV-2, MERS-CoV, viral entry, epithelial, TMPRSS2 inhibitor, lung cell, PROTECT,